Jerry Kanellos Form 3 Filing for Immuron Ltd - Officer Holdings and Performance Rights

This Form 3 filing reports the initial statement of beneficial ownership by Jerry Kanellos, Chief Scientific Officer of Immuron Ltd. The filing discloses Kanellos' holdings as of March 18, 2026, including direct ownership of 333,000 ordinary shares. Additionally, the filing reports two sets of performance rights: 179,664 performance rights granted on July 12, 2023, with an exercise price of $0 and expiration on July 12, 2027; and 272,134 performance rights granted on October 24, 2024, with an exercise price of $0 and expiration on June 30, 2029. The 2024 performance rights have vesting schedules, with 217,707 becoming exercisable on July 23, 2025, and 54,427 on October 29, 2025. All holdings are reported as direct ownership.